Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders
SAN DIEGO & SHANGHAI–(BUSINESS WIRE)–Sirius Therapeutics today announced it has submitted an application in Australia to begin a first-in-human clinical trial of SRSD107, its next generation siRNA therapeutic for the prevention and treatment of thromboembolic disorders. SRSD107, which specifically targeting coagulation factor XI (FXI), is the first Sirius-developed compound to reach clinical stage of development globally.
“We have made rapid progress in developing SRSD107 and other candidates in our pipeline since Sirius was established two years ago. This submission marks our transition from discovery to clinical stage development,” said Dr. Qunsheng Ji, Sirius Therapeutics Chief Executive Officer. “The exceptional durability of pharmacology and safety profile suggests SRSD107 has the potential to be a Best- and First-in-class FXI siRNA therapeutic. We aspire to develop SRSD107 as a transformative medicine with a dosing schedule of once semiannually or potentially annually for patients who need chronic anticoagulant.”
About Thromboembolic Disorders
Thrombosis is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism (VTE). According to a study in The Lancet of reginal and global mortality, thromboembolic disorders are estimated to cause 1 in 4 deaths worldwide1.
About SRSD107
SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. Preclinical in vivo studies demonstrated near 100% reduction of FXI levels for up to 6 months, without bleeding events after a single subcutaneous dose.
About Sirius Therapeutics
Sirius is an innovative biotech company developing next generation siRNA therapy for global markets. We are dedicated to discovering and developing new treatment options for cardiovascular disease patients.
Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the United States and translational medicine center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and the leadership team.
[1] Lozano R, Naghavi M, Foreman K, et al. Lancet. 2012;380, 2095-1128.
Contacts
Recent Posts
“One Earth Summit” 2025 Held Successfully Hong Kong Fully Leverages Its Role as an International Financial Center and Leader in Green Finance
Laying a Solid Foundation for the Development of ESG Investment and Green Innovation Calling for…
The Campaign “It’s Time for EU Beef” is coming to Cebu and Manila in April
The Philippine meat industry will be shown the quality and guarantees of European beef MANILA,…
European beef will continue to play aleading role in Singapore in the coming months of 2025
"It’s Time for European Beef" is a campaign led by Provacuno and co-funded by the…
Make Waves at Galaxy Macau: Dive into a Luxurious One-Stop Ultimate Holiday Escape with the Reopening of the Grand Resort Deck
MACAU SAR - Media OutReach Newswire - 27 March 2025 - The world-class luxurious Galaxy…
Diabetes Association Unveils T-CaReMe Taipei Declaration at the Asia Diabetes International Conference
In an effort to achieve a target of 80% of patients controlling the three highs…
Li Ning Company Limited Announces 2024 Annual Results
Strengthen the “Single Brand, Multi-Categories, Diversified Channels” Strategy | Solidify Brand and Product Competitiveness, Ensure…